PRESAMINE
LOE ApproachingNDAORALTABLETPriority Review
Approved
Apr 1959
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 19h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PRESAMINE is an oral small-molecule tablet approved in 1959 by Sanofi as an NDA product. The generic name and specific mechanism of action are not publicly disclosed in available data. This legacy drug represents a foundational product in Sanofi's portfolio with decades of clinical use.
LOE Approaching
As loss-of-exclusivity approaches, commercial teams face declining revenue and reduced headcount; roles focus on lifecycle extension, generic partnerships, or portfolio transition.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job openings reflect the product's mature, declining lifecycle stage. Working on PRESAMINE offers limited growth but valuable experience in lifecycle management, generic defense, and portfolio wind-down strategies.
Brand ManagerField Sales Representative
Worked on PRESAMINE at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.